Roche shares gain on weight loss drug results in trial
In December, Roche agreed to take over unlisted obesity drug developer Carmot for $2.7bn upfront
16 May 2024 - 09:51
byLudwig Burger
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Roche shares gained 4.7% at the market open on Thursday after an early-stage trial showed that the obesity drug candidate by newly acquired Carmot Therapeutics led to significant weight loss.
The Swiss drugmaker said the study in the first of three trial stages required for regulatory approval showed the compound known as CT-388 resulted in weight loss of 18.8%, when adjusted for a placebo effect, after 24 weeks in healthy adults with obesity.
In December, Roche agreed to take over unlisted obesity drug developer Carmot for $2.7bn upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.
Once-a-week injection CT-388 is Carmot’s most promising drug candidate, mimicking the effect to two gut hormones GLP-1 and GIP like Lilly’s Mounjaro, also known as Zepbound.
Support our award-winning journalism. The Premium package (digital only) is R30 for the first month and thereafter you pay R129 p/m now ad-free for all subscribers.
Roche shares gain on weight loss drug results in trial
In December, Roche agreed to take over unlisted obesity drug developer Carmot for $2.7bn upfront
Roche shares gained 4.7% at the market open on Thursday after an early-stage trial showed that the obesity drug candidate by newly acquired Carmot Therapeutics led to significant weight loss.
The Swiss drugmaker said the study in the first of three trial stages required for regulatory approval showed the compound known as CT-388 resulted in weight loss of 18.8%, when adjusted for a placebo effect, after 24 weeks in healthy adults with obesity.
In December, Roche agreed to take over unlisted obesity drug developer Carmot for $2.7bn upfront, joining a list of contestants seeking to challenge the dominant makers of weight-loss drugs Novo Nordisk and Eli Lilly.
Once-a-week injection CT-388 is Carmot’s most promising drug candidate, mimicking the effect to two gut hormones GLP-1 and GIP like Lilly’s Mounjaro, also known as Zepbound.
Reuters
Amgen opts for different route to weight-loss windfall
Biotech M&A spree buoys healthcare dealmakers before US conference
Roche takes on weight-loss drug firms
Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.
Please read our Comment Policy before commenting.
Most Read
Published by Arena Holdings and distributed with the Financial Mail on the last Thursday of every month except December and January.